Yasuhito Tanaka
Kumamoto University
983 Papers
7K Citations
Yasuhito Tanaka is an academic researcher from Kumamoto University. The author has contributed to research in topics: Hepatitis B virus & Medicine. The author has an hindex of 69, co-authored 870 publications. Previous affiliations of Yasuhito Tanaka include South Valley University & National Institute of Advanced Industrial Science and Technology.
Chat about Author
Papers
Eight genotypes (A–H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics
Hideaki Kato,Robert G. Gish,Natalie Bzowej,Margaret Newsom,Fuminaka Sugauchi,Yasuhito Tanaka,Takanobu Kato,Etsuro Orito,Sadakazu Usuda,Ryuzo Ueda,Yuzo Miyakawa,Masashi Mizokami +11 more
TL;DR: Eight HBV genotypes (A–H) were identified in San Francisco in association with various ethnicities and then influenced ALT levels as well as the prevalence of serum HBeAg.
76
Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong.
Man-Fung Yuen,Erwin Sablon,Yasuhito Tanaka,Takanobu Kato,Masashi Mizokami,Joke Doutreloigne,He-Jun Yuan,Danny Ka-Ho Wong,Siu-Man Sum,Ching-Lung Lai +9 more
TL;DR: B and C were the two most common HBV genotypes in Hong Kong, the former had a higher chance of earlier HBeAg seroconversion and lower ALT levels and the former was lower in patients with age <50, probably related to influx of immigrants from China since 1949.
74
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Hidenori Toyoda,Takashi Kumada,Toshifumi Tada,Koichi Takaguchi,Toru Ishikawa,Kunihiko Tsuji,Mikio Zeniya,Etsuko Iio,Yasuhito Tanaka +8 more
TL;DR: The therapy with daclatasvir and asunaprevir has high antiviral efficacy in patients receiving hemodialysis with a comparable safety profile to patients without renal dysfunction.
Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools.
Hiromi Ito,Atsushi Kuno,Hiromichi Sawaki,Maki Sogabe,Hidenori Ozaki,Yasuhito Tanaka,Masashi Mizokami,Junichi Shoda,Takashi Angata,Takashi Sato,Jun Hirabayashi,Yuzuru Ikehara,Hisashi Narimatsu +12 more
TL;DR: A new strategy for glyco-alteration analysis of glycoproteins by using multiple glycan profiling tools is introduced, successfully identified glycan alterations on alpha-fetoprotein (AFP), including a novel LacdiNAc structure in addition to previously reported alterations such as alpha1,6 fucosylation.
74
When Should “I” Consider a New Hepatitis B Virus Genotype?
TL;DR: A new hepatitis B virus strain isolated in Vietnam is described and claimed to be a “new genotype,” “HBV genotype I,’ with a complex recombination involving genotypes C, A, and G, and it is refuted.